| Year | 2000–2002 | 2003–2005 | 2006–2008 | 2009–2011 | 2012–2014 | 2015–2016 |
|---|---|---|---|---|---|---|
| N=248 | N=337 | N=444 | N=462 | N=436 | N=178 | |
| Disease duration (y) | 6.1±4.0 | 5.1±4.0 | 4.2±3.7 | 3.7±3.0 | 3.3±3.1 | 3.4±3.0 |
| JIA category (%) | 20.6 | 12.2 | 4.3 | 3 | 1.4 | 0.6 |
| Sys JIA | 25.8 | 31.8 | 32.9 | 36.6 | 33 | 33.7 |
| RFneg PA | 12.5 | 11.0 | 8.1 | 8 | 3.7 | 9.0 |
| RFpos PA | 2.4 | 4.5 | 6.1 | 6.1 | 3.4 | 5.1 |
| PersOA | 18.1 | 13.1 | 21.4 | 22.3 | 21.3 | 21.9 |
| Ext OA | 9.7 | 14.7 | 16.4 | 13.6 | 26.1 | 22.5 |
| ERA | 4.8 | 8.9 | 7.7 | 7.8 | 8 | 4.5 |
| PsA unclass JIA | 6 | 3.6 | 3.2 | 2.6 | 3 | 2.8 |
| Uveitis | 12.1 | 5.7 | 10.2 | 5.4 | 4.1 | 2.3 |
| Baseline concom. NSAID/steroids/MTX/other DMARDS (%) | 90.3/53.2/77.8/5.2 | 88.7/42.7/76.3/5 | 84.9/32.4/69.1/3.8 | 71/31/68.4/3.7 | 78.7/27.3/61/6.7 | 74.2/18.5/62.9/4.5 |
| Active joints | 10.3±9.8 | 9.0±9.4 | 7.8±9.0 | 6.2±8.0 | 4.9±6.5 | 4.6±5.5 |
| Phy VAS (0–10) | 6.8±2.4 | 5.8±2.6 | 5.2±2.6 | 4.9±2.9 | 5.0±2.6 | 4.8±2.5 |
| Pat VAS (0–10) | 5.7±2.7 | 5.4±2.7 | 4.8±2.6 | 3.7±2.7 | 3.7±2.6 | 3.7±2.3 |
| CHAQ | 1.0±0.8 | 0.8±0.7 | 0.7±0.6 | 0.6±0.6 | 0.5±0.6 | 0.5±0.5 |
| CRP in mg/l | 44.6±56.8 | 25.2±32.2 | 18.2±32.1 | 10.6±19.1 | 9.8±29.1 | 8.9±18.1 |
| JADAS10 | 21.4±7.7 | 18.5±7.5 | 16.6±6.7 | 14.1±8.7 | 13.3±6.8 | 13.3±8.7 |
Changes in all parameters were significant (p<0.001) in Kruskal-Wallis-Test/Chi-quare.